EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection

Chia-Ling Yu iD, Andre F Carvalho, Trevor Thompson iD, Tzu-Cheng Tsai, Ping-Tao Tseng iD, Chih-Wei Hsu iD, Yu-Kang Tu iD, Szu-Nian Yang iD, Tien-Wei Hsu iD, Ta-Chuan Yeh, Chih-Sung Liang iD

International Journal of Environmental Research and Public Health · 2023

DOI: 10.3390/ijerph20054088 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Chia-Ling Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chang-Gung Memorial Hospital, Linkou 244, Taiwan. Hauptthemen laut MEDLINE: Clinical Deterioration, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preliminary meta-analyses suggested that fluvoxamine was effective in treating COVID-19 infection. However, the reliability of this evidence has not yet been examined. MEDLINE, CENTRAL, EMBASE, PsycINFO, and ClinicalTrials.gov were searched to identify any randomized controlled trials (RCTs) from the inception of the databases to 5 February 2023. We used trial sequential analysis (TSA) to examine the reliability of the current existing evidence on the benefits of fluvoxamine on COVID-19 infection. The primary outcome was clinical deterioration, as defined in the original study (reported as odds ratio (OR), with 95% confidence intervals), and the secondary outcome was hospitalization. In the TSA, we used the relative risk reduction thresholds of 10, 20, and 30%. The updated meta-analysis of the five RCTs showed that fluvoxamine was not associated with lower odds of clinical deterioration when compared with a placebo (OR: 0.81; 0.59–1.11). The effect of fluvoxamine lay within the futility boundary (i.e., lack of effect) when using a 30% relative risk reduction threshold. The effect estimates lay between the superiority and futility boundary using the 10% and 20% threshold, and the required size of information was not reached for these two thresholds. The effect of fluvoxamine on the odds of hospitalization was not statistically significant (0.76; 0.56–1.03). In conclusion, there is no reliable evidence that fluvoxamine, when compared to a placebo, reduces the relative risk of clinical deterioration among adult patients with COVID-19 infection by 30%, and a relative risk reduction of 20% or 10% is still uncertain. The role of fluvoxamine as a COVID-19 treatment cannot be justified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical DeteriorationCOVID-19HumansAdultFluvoxamineCOVID-19 Drug TreatmentPatients

Stichwörter der Autor:innen

COVID-19deteriorationfluvoxaminemeta-analysistrial sequential analysis

Substanzen

Fluvoxamine

Autor:innen und Institutionen

  • Department of Pharmacy, Chang-Gung Memorial Hospital, Linkou 244, Taiwan.
  • IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC 3220, Australia.
  • Centre for Chronic Illness and Ageing, University of Greenwich, London SE10 9LS, UK.
  • Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung 811, Taiwan.
  • Department of Psychology, College of Medical and Health Science, Asia University, Taichung 413, Taiwan.
  • Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.

ORCID-Profile: Chia-Ling Yu, Trevor Thompson, Ping-Tao Tseng, Chih-Wei Hsu, Yu-Kang Tu, Szu-Nian Yang, Tien-Wei Hsu, Chih-Sung Liang

Zitieren

APA

Yu, C. L., Carvalho, A. F., Thompson, T., Tsai, T. C., Tseng, P. T., Hsu, C. W., Tu, Y. K., Yang, S. N., Hsu, T. W., Yeh, T. C., & Liang, C. S. (2023). Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20054088

Vancouver

Yu CL, Carvalho AF, Thompson T, Tsai TC, Tseng PT, Hsu CW, et al. Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20054088

BibTeX
@article{Yu2023,
  author = {Yu, Chia-Ling and Carvalho, Andre F and Thompson, Trevor and Tsai, Tzu-Cheng and Tseng, Ping-Tao and Hsu, Chih-Wei and Tu, Yu-Kang and Yang, Szu-Nian and Hsu, Tien-Wei and Yeh, Ta-Chuan and Liang, Chih-Sung},
  title = {Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection},
  journal = {International Journal of Environmental Research and Public Health},
  year = {2023},
  doi = {10.3390/ijerph20054088}
}
Kostenlos starten →